Biometrik Riset Indonesia Explores Central Java Through Strategic Visits: Insights from Semarang, Solo, and Yogyakarta

Writer and Editor : Denia Zalfaa Marwaa Evangeulista

Semarang, Solo, and Yogyakarta, June 03-07, 2024 - PT Biometrik Riset Indonesia, a company specializing in research services and focusing on conducting Bioequivalence studies, recently embarked a series of productive visits to pharmaceutical sponsors in Semarang, Solo, and Yogyakarta. These visits aimed to foster closer ties and explore innotiative bioequivalence partnerships with pharmaceutical sponsors.

These visits were marked by productive and insightful discussions with six pharmaceutical industries in Central Java. It started with PT Erela, PT Zenith, PT Nufarindo, and PT Sampharindo in Semarang, continued to PT Ifars in Solo, and wrapped up with PT Berlico in Yogyakarta. Upon arrival, Biometrik team was warmly welcomed by all of these six pharmaceutical companies. The agenda focused on exchanging knowledge, discussing the readiness of drug formulas slated from each pharmaceutical sponsors for bioequivalence testing, and exploring potential research for future collaborations.

Biometrik Riset Indonesia’s commitment is to enhancing drug development processes and ensuring the efficacy and safety of pharmaceutical products. Along with that, Biometrik’s mission is to conduct reliable, rapid, and high-quality research services on bioequivalence studies with conformance to current national and/or international standards and guidelines.

The response from the Central Java pharmaceutical company was overwhelmingly positive. Companies expressed great interest in collaborating with Biometrik on bioequivalence testing for their drug formulas. By the end of these visits, Biometrik had successfully laid the groundwork for future collaborations and strengthened partnership bonds across these three cities, each step bringing them closer to the goal to be a part of pharmaceutical research and development advancement in Indonesia.